Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015684 · ClinicalTrials.gov registry record · Phase 1
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
A Phase 1 study of Sickling Disorder Due to Hemoglobin S, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07015684 is a Phase 1 study of Sickling Disorder Due to Hemoglobin S that is actively recruiting participants, run by Columbia University. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07015684, a Phase 1 study of Sickling Disorder Due to Hemoglobin S, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find the smallest amount of the 131 I-apamistamab needed for preparing patients with severe sickle cell disease (SCD) for a bone marrow transplant. This is the first time 131 I-apamistamab is being used for advanced Sickle Cell Disease (SCD) in the setting of allogeneic stem cell transplant. 131 I-apamistamab is an investigational product. This means that 131 I-apamistamab has not been approved by the Food and Drug Administration (FDA) for medical use in patients. The study treatment that is given before the transplant is called the conditioning regimen. In this study, the investigators are adding a drug called 131 I-apamistamab instead of the conditioning regimen typically given before a stem cell transplant.
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG 131I-apamistmab
- DRUG Campath
- DRUG Total Body Irradiation
- PROCEDURE Exchange Transfusion
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2032-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07015684
The ClinicalTrials.gov registry entry for NCT07015684 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickling Disorder Due to Hemoglobin S appearing as the primary indexed condition, and to 5 interventions - of which Sirolimus is the first listed.
NCT07015684 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07015684 about?
NCT07015684 is a clinical study titled "131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)". The purpose of this study is to find the smallest amount of the 131 I-apamistamab needed for preparing patients with severe sickle cell disease (SCD) for a bone marrow transplant. This is the first time 131 I-apamistamab is being used for advanced Sickle Cell Disease (SCD) in the setting of allogene...
What is the current status of trial NCT07015684?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-04-28. Estimated completion is 2032-03-12.
What conditions does trial NCT07015684 study?
This clinical trial studies the following conditions: Sickling Disorder Due to Hemoglobin S.
What interventions are being tested in trial NCT07015684?
The interventions under investigation include: Sirolimus (DRUG), 131I-apamistmab (DRUG), Campath (DRUG), Total Body Irradiation (DRUG), Exchange Transfusion (PROCEDURE).
Who is sponsoring clinical trial NCT07015684?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015684 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.